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The 4-aminoquinoline bisquinoline piperaquine is an important partner drug in one of the presently recommended artemisinin
combination therapies. Recent clinical trials have confirmed its high efficacy in combination with dihydroartemisinin. Resis-
tance to piperaquine alone has, however, been documented. Amplification in copy number of the Plasmodium falciparum multi-
drug resistance locus on chromosome 5, containing the pfmdr1 gene, has been shown to confer resistance to structurally unre-
lated antimalarials. Through the determination of the 50% inhibitory concentrations (IC50s) and IC90s for piperaquine and
chloroquine in a set of 46 adapted P. falciparum cultures originating from the Thai-Burmese border, we have characterized the
regions around the pfmdr1 gene and identified a significant association between the presence of pfmdr1 duplications and en-
hanced sensitivity to piperaquine (P  0.005 for IC50 and P  0.002 for IC90) and chloroquine, reaching statistical significance at
IC90s (P  0.026). These results substantiate the potential importance of pfmdr1 copy number amplifications in the efficacy of
the combination therapy piperaquine-dihydroartemisinin. It supports the rational use of 4-aminoquinolines and artemisinin-
based compounds, as they independently select for mutually incompatible combinations of mutations.
Artemisinin combination therapy (ACT) is instrumental in theglobal decrease of Plasmodium falciparum malaria in recent
years. However, P. falciparum resistance to several partner drugs,
namely, artesunate-mefloquine (25), artemether-lumefantrine
(26, 31), and artesunate-amodiaquine (15), has been docu-
mented. These early signs have been associated with decreased
parasite responses to the slowly eliminated partner drugs, a phe-
nomenon believed to be accelerated in circumstances of high
transmission due to the exposure of reinfecting parasites to sub-
therapeutic concentrations (14).
A more recent ACT, dihydroartemisinin-piperaquine (DHA-
PPQ), has been widely used in Southeast Asia and is now ready to
be launched in sub-Saharan Africa. PPQ is a bisquinoline, struc-
turally a 4-aminoquinoline-based antimalarial like chloroquine
(CQ). Piperaquine is not a recent newcomer, having been exten-
sively used in monotherapy regimens in the southern regions of
China in the 1970s and 1980s, as a response to the rise of CQ
resistance. Later, it was adopted by the national Vietnamese ma-
laria control program in several formulations (9). The most recent
development of PPQ-based ACT is commercially known as
Artekin(HollekynPharmaceuticals,China)orEurartesim(Sigma-
Tau, Italy), each tablet containing 40 mg dihydroartemisinin plus
320 mg piperaquine phosphate.
DHA-PPQ has shown excellent efficacy in recent clinical trials
in Africa (1, 4, 17), making it a promising fixed-dose formulation
for malaria treatment on the continent. Nevertheless, the PPQ
long elimination half-life of 4 weeks after the standard 3-day
course (2.25 mg/kg [of body weight] DHA and 18 mg/kg of pip-
eraquine phosphate per day) raises concerns about the long-term
sustainability of its efficacy in African high-transmission settings
(22). Furthermore, P. falciparum resistance to PPQ has long been
documented, albeit in the context of monotherapy (9). In this
scenario, the search for molecular markers of early detection of
PPQ resistance is increasingly important. Interestingly, the
pfmdr1 (multidrug resistance 1) N86Y and pfcrt (chloroquine re-
sistance transporter) K76T CQ resistance markers, known to con-
fer different degrees of resistance to the common 4-aminoquino-
lines, have not been consistently associated with parasite response
to PPQ either in vitro (5) or in vivo (32).
Copy number variation (CNV) polymorphism at the multi-
drug resistance locus pfmdr1 in chromosome 5 is well known in
Southeast Asian settings to be associated with susceptibility to
antimalarial drugs both in vitro (2, 7, 36) and in vivo (24–26). CNV
events in this chromosomal region normally involve more than
the pfmdr1 gene. In fact, the amplification includes a genomic
fragment that can reach 100 kb, encompassing multiple genes (12,
34). These amplified genome regions (amplicons) have been
structurally characterized in field samples from the Thailand-
Burma border (21), although the precise importance and impact
of their diversity in the development of drug resistance are yet to
be investigated.
Recently, it has been reported that the use of PPQ in Vietnam is
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associated with a significant decrease in the prevalence of pfmdr1
gene duplications in the parasite population of this region (16).
Trying to identify the genetic basis of PPQ resistance, a recent
study showed that continuous in vitro exposure leads to a deam-
plification of the amplicon encompassing the pfmdr1 gene and
amplification of a neighboring upstream region on chromosome 5
(11). This, associated with previous observations of decreased
copy number in parasites long exposed to chloroquine (2), led us
to hypothesize that gene copy number amplifications in pfmdr1
and its amplicon size might lead to an increased sensitivity to PPQ.
MATERIALS AND METHODS
Parasite adaptation and in vitro drug susceptibility assays. We analyzed
46 strains previously culture adapted from the region of Mae Sot, in the
Thai-Myanmar border, from clinical cases occurring between 2002 and
2008, specifically, 1 strain from 2002, 4 strains from 2007, and 41 strains
from 2008 (36). The study was ethically cleared by the relevant institu-
tions, the blood samples having been obtained upon informed consent
provided in the local language.
The maintenance medium for the parasite cultures contained 5% he-
matocrit (O erythrocytes) in RPMI 1640 (GIBCO BRL; Invitrogen
42402-010) supplemented with 1 L-glutamine (GIBCO BRL; Invitrogen
25030-032), 25 g/ml gentamicin (GIBCO BRL; Invitrogen 15750-037),
and 10% human serum. Piperaquine monophosphate (molecular weight
[MW], 633.5) was obtained from AvaChem (San Antonio, TX), and chlo-
roquine diphosphate (MW, 515.86) was purchased from Sigma-Aldrich
(St. Louis, MO). The inhibitory concentrations (ICs) were determined
through the histidine-rich protein 2-based double-site sandwich enzyme-
linked immunosorbent assay (ELISA) (23). Briefly, 200 l of synchro-
nized culture at ring stage containing 0.05% parasitemia and 1.5% hemat-
ocrit was precoated in 96-well culture plates (titration of 1/2), with a PPQ
concentration in row 8 of 200 nM and a CQ concentration of 2 M.
Cultures were incubated at 37°C in a candle jar (33) for 72 h, followed by
the lysis of the cells by freeze-thawing for ELISA analysis. Four indepen-
dent assays were performed for each field strain, and the 3D7 reference
strain 50% IC (IC50) was measured for drug quality and efficacy control.
The 3D7 strain was kindly provided by the late D. Walliker (Department
of Animal and Population Genetics, University of Edinburgh, United
Kingdom).
Molecular analysis. Extraction of genomic DNA (gDNA) of the 46
Thai strains and its molecular characterization, including pfmdr1 N86Y,
pfcrt K76T single nucleotide polymorphisms (SNPs), and pfmdr1 gene
copy number variation, were previously performed (36).
In order to better understand the importance for drug resistance of the
amplified regions at chromosome 5, all strains carrying an increased
pfmdr1 copy number (24 strains), as well as the laboratory strains FCB,
FCR3, F32, and Dd2, known to carry multiple copies of this gene, were
further characterized for their approximate amplicon size through real-
time PCR of the pfmdr1-adjacent regions.
The software program Primer Express 2.0 (Applied Biosystems, CA)
was used for the design of 20 sets of TaqMan probes and primers to
quantify the CNV at relevant chromosome 5 regions. This scanning ap-
proach covered a ca. 157-kb fragment containing the pfmdr1 gene (see
Table S1 in the supplemental material).
The -tubulin gene (PF10_0084) was used as the single-copy endog-
enous control as previously described (25). We estimated the copy num-
ber of the target sequence in relation to a standard calibrator lab strain
genome (3D7; single pfmdr1 copy) by using the cycle threshold (CT)
method.
All assays were performed at least in triplicate on 96-well plates using
the ABI PRISM 7000 sequence detection system (Applied Biosystems,
Fresno, CA). The detection threshold was set above the mean baseline
value for the first 6 to 15 cycles.
Following the previous findings that in vitro exposure of PPQ in strain
Dd2 leads to an amplification of the fragment (spanning from PFE1010w
to the PFE1085w gene) identified by Eastman et al. at chromosome 5, we
scrutinized all Thai samples (n  46) for CNV polymorphism in the
PFE1010w and PFE1085W loci. Primers and probes as well as the real-
time PCR conditions were as Eastman et al. described (11).
Statistical analysis. Piperaquine and chloroquine 50% and 90% in-
hibitory concentrations were calculated by nonlinear regression analysis
(http://malaria.farch.net). Statistical analysis was carried out using Sigma-
Plot for Windows, version 11.0. Pearson correlation was used to assess
linear relations of PPQ and CQ. The associations between the in vitro PPQ
susceptibility values (IC50 and IC90) and the pfmdr1 gene copy numbers
were tested through the performance of the t test, and when the normality
test failed (Shapiro-Wilk), the Mann-Whitney rank sum test was applied.
RESULTS
The 50% and 90% inhibitory concentrations (IC50s and IC90s)
were successfully determined for PPQ and CQ in the 46 P. falcip-
arum strains. A large range of sensitivities was recorded for PPQ,
with a median IC50 of 39.4 nM, from 13.8 to 108.2 nM (see Table
S2 in the supplemental material). All strains were found to be
highly resistant to CQ, with an IC50 of 450 nM. The interaction
between PPQ and CQ ICs was tested with Pearson correlation
analysis. It was agonistic both for IC50s (correlation coefficient of
0.37; P  0.01) and IC90s (correlation coefficient  0.40; P 
0.006).
Out of the 46 strains analyzed, 24 carried increased pfmdr1
copy numbers. Specifically, 16 strains carried two copies, 6 strains
carried three copies, and 2 strains harbored four copies of the
pfmdr1 gene. A significant association was found between the
pfmdr1 gene copy number amplifications and a decrease in
the IC50s for PPQ (geometric mean of 42.9 nM for strains with
pfmdr1 CNV of 1 versus geometric mean of 29.2 nM for the strains
with pfmdr1 CNV of 1; P  0.002). The same pattern was ob-
served for the IC90s for CQ (P  0.026) (Fig. 1). Stratifying the
strains with 1 pfmdr1 copy (2, 3, or 4 copies) did not, however,
reveal any trend of progressive enhanced PPQ or CQ sensitivity.
In order to find any association with the in vitro drug outcome
phenotype and the type of amplified fragment containing the
pfmdr1 gene, the approximate amplicon size and structure (i.e.,
which loci were involved) were characterized in the 24 Thai strains
and in the reference strains FCB, FCR3, F32, and Dd2. Six differ-
ent types of amplicons were found in the Thai samples (types a to
f [Fig. 2]). Two amplicon types were found in the reference lab
strains, with amplicon size and position on chromosome 5 illus-
trated as vertical pink bars in Fig. 2. The amplicon varied in size
from approximately 14 to 100 kb, spanning different genes. All the
characterized amplicons in the Thai strains were found to be
smaller than the structure present in the analyzed reference
strains.
We found no significant associations between the types of am-
plicon (types a to f) and the determined ICs for PPQ and CQ.
Considering the previously determined phenotypes (36), signifi-
cance difference was detected where parasites carrying amplicon
type a are associated with significantly higher mefloquine IC50s
(P  0.01) (Table 1). A trend in increased IC50 is also detected for
the same type of amplicon with artemisinin (ART) and lumefan-
trine (LUM), although statistically nonsignificant (Table 1).
A region from the PFE1010w gene to the PFE1085w locus,
located ca. 72 kbp upstream of the pfmdr1 gene (Fig. 2, dashed
green box), has been previously associated with in vitro PPQ re-
sistance (11). However, no increase in copy number for the
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PFE1010w and PFE1085w genes was found among our 46 field
strains.
DISCUSSION
The ACT DHA-PPQ has shown excellent efficacy in field clinical
trials, making it a promising fixed-dose formulation for the con-
trol of malaria. The recent detection of ART resistance in South-
east Asia (10), in regions where the partner drug (mefloquine) is
failing (6), supports the importance of maintaining the integrity
of the efficacy of the long-standing partner drug. With its very
long half-life, PPQ is potentially at risk in settings of high trans-
mission, due to the possibility of a large posttreatment drug resis-
tance selection window, akin to what has been seen with other
ACTs (15, 31). This, associated with the knowledge that PPQ re-
sistance has already emerged in the past (13), commands urgency
regarding the research of its molecular mechanisms. Additionally,
it should be noted that emerging drug resistance has even been
suggested as an explanation for an unexpected low cure rate of the
DHA-PPQ ACT in a clinical trial conducted in Papua New Guinea
(18).
In the present study, a large range of sensitivities was registered
for PPQ, covering almost 1 log of IC50s. According to the previous
genotype data for the herein-analyzed parasites (36), this large
range of sensitivities cannot be explained by the monomorphic
pfcrt gene, nor by the SNPs found in the pfmdr1 and pfmrp1 genes.
The noninvolvement of pfmdr1 and pfmrp1 SNPs in the parasite’s
response to PPQ mirrors recent similar studies conducted in Ken-
yan isolates (19) as well as other studies in vitro (5) and in vivo
(32).
On the other hand, we have found for the first time evidence
that increased copy number of pfmdr1 sensitizes the parasite to
PPQ. The P-glycoprotein homologue 1 (Pgh1) encoded by pfmdr1
is almost exclusively located in the parasite food vacuole (FV) (8),
facing the lumen of the organelle (29), consistent with the pres-
ently accepted model of this transporter being an importer of sol-
FIG 2 Genomic characterization of amplified regions. Vertical bars charac-
terize amplicon size and position on chromosome 5 (left y axis), including
information for genes in the sequence (right y axis). Pink bars illustrate am-
plicon type for the lab strains, and blue bars different amplicons found in the
Thai strains (n  24) all carrying pfmdr1 copy number amplifications (gene
highlighted in red). The green box highlights a genomic region previously
found to be associated with decreased susceptibility to PPQ (11) which is not
found in the Thai strains. The left y axis shows the position on chromosome 5,
and the right y axis shows the gene annotation relative to the 3D7 genome
sequence. Genes with known or putative function described in the depicted
genomic position were acquired from NCBI Map viewer at http://www.ncbi
.nlm.nih.gov. The nonannotated genes represent hypothetical proteins with
unknown function.
FIG 1 pfmdr1 copy number variation (CNV) and in vitro IC50s and IC90s of PPQ and CQ. Shown is the association between the geometric mean of in vitro PPQ
and CQ ICs and the pfmdr1 CNV polymorphism. Data are described in Table S2 in the supplemental material. Black bars, single copy of the pfmdr1 gene (22
strains); gray bars, more than 1 pfmdr1 gene copy (24 strains). The t test was applied to determine significant difference. Error bars represent standard errors of
the means.
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utes toward the FV (28). Such function implies that the presence
of increased pfmdr1 copy numbers (expected to lead to an increase
of Pgh1 load in the FV membrane) is associated with an enhanced
accumulation of PPQ in the organelle. The increased susceptibil-
ity to PPQ hence suggests that the target of this drug is located in
the FV, as in the case of CQ, another 4-aminoquinoline. This
hypothesis is supported by the positive correlation we found in the
parasite IC response to PPQ and CQ. It is, however, important to
note that although PPQ is structurally related to CQ, these two
drugs must be associated with other relevant mechanisms of resis-
tance, as PPQ remains active against CQ-resistant parasites (3).
As for CQ, all strains were highly resistant to this drug. pfcrt
mutations, in particular at amino acid position 76, are a central
factor for CQ resistance. The pfcrt gene in this set of Thai samples
was found to be totally monomorphic of the Dd2 type, which
explains the fact that all the parasites were highly resistant to this
drug (i.e., IC50  100 nM threshold) but does not explain the large
variation that was observed between them. Interestingly, we could
see a trend where decreased pfmdr1 copy number polymorphism
tends to coincide with higher ICs, reaching statistical significance
at IC90s (Fig. 1). The inverse relation between CQ resistance and
pfmdr1 copy number has previously been documented in vitro (2)
but not observed in highly controlled gene knockdown experi-
ments (30), possibly indicative of an effect visible only in certain
genomic environments (e.g., possibly the presence of the pfmdr1
86N allele).
It has long been known that the duplication events involving
pfmdr1 vary in size while spanning different genes in different
parasites (12, 20, 27, 34). We tried to further investigate if the type
(i.e., which genes are included) and size of the amplicon influence
drug susceptibility phenotypes. Overall, the field strains were
found to carry smaller amplicons than were lab strains (Fig. 2),
possibly due to a fitness cost, consistent with previous reports of
intrahost population dynamics (35). Selection of parasites with
smaller amplicons may be favored due to the reduced costs asso-
ciated with the lower number of genes and/or replication of un-
necessary DNA (20). This penalty might also be the underlying
reason for the trend observed for the amplicon type a to be asso-
ciated with significant decreased susceptibility to mefloquine and
the observed trend for ART and LUM (Table 1). Further studies
are warranted to explore the relationship between amplicon size
and drug activity.
To elucidate potential determinants of resistance to PPQ, a
recent work based on continuous exposure to PPQ was able to
select parasites with IC50s 100-fold greater than that for the par-
ent line (Dd2). Applying comparative genome hybridization pro-
cedures on these parasites allowed the detection of a new amplifi-
cation fragment neighboring the amplicon containing the pfmdr1
gene (11) (see Fig. 2, green dashed box). The Thai samples herein
analyzed did not show events of genomic amplification in this
region. It is possible that this has to do with the fact that PPQ has
not been widely used in western Thailand, where these parasites
originated. It is of particular interest to analyze this genomic re-
gion on parasites from locations where PPQ has been used in
national malaria control programs—like Vietnam or Papua, In-
donesia—in order to identify relevant DNA changes.
Our data reinforce the notion that pfmdr1 copy number am-
plifications are selected out by the use of 4-aminoquinolines, in
contrast with what is observed with amino alcohol quinolines (lu-
mefantrine and mefloquine) (25, 26, 30). Such effects, which mir-
ror those previously observed for the pfmdr1 N86Y SNP (15, 31),
support the rational use of 4-aminoquinoline and amino alcohol
quinoline-based ACTs as alternative first- and second-line che-
motherapies in malaria control programs, as potentially they in-
dependently select for mutually incompatible combinations of
mutations.
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ARTc DHAc MQc LUMc PPQ CQ
pfmdr1 CNV
 1 22 4.4 (0.6)d 1.3 (0.3) 49.1 (19.7)d 8.6 (1.8)d 49.7 (7.8) 676.1 (40.9)
1 24 11.0 (1.1) 1.5 (0.5) 159.1 (26.6) 18.9 (2.7) 32.2 (5.2) 601.0 (25.8)
Amplicon type
a 3 14.8 (4.7) 2.4 (1.2) 243.6 (16.5)e 26.0 (6.8) 35.5 (8.7) 585.3 (17.2)
b 6 8.1 (2.1) 0.9 (0.2) 113.3 (31.6) 13.6 (2.7) 28.2 (4.8) 569.2 (23.6)
c 2 11.3 (7.0) 1.0 (0.4) 130.4 (23.6) 21.1 (5.7) 35.3 (8.6) 592.9 (12.7)
d 3 6.7 (1.9) 1.0 (0.3) 135.2 (34.7) 10.4 (1.7) 32.5 (4.5) 588.7 (9.5)
e 8 12.7 (1.1) 1.8 (0.5) 170.9 (13.8) 21.9 (1.4) 35.0 (5.9) 638.8 (28.3)
f 2 12.9 (5.1) 2.6 (1.5) 186.4 (4.7) 22.8 (2.8) 25.1 (2.2) 594.9 (109.9)
a PPQ, piperaquine; ART, artemisinin; DHA, dihydroartemisinin; MQ, mefloquine; LUM, lumefantrine; CQ, chloroquine. Pearson correlations (correlation coefficients [r]) with
the PPQ IC50 were as follows: for ART, r  0.03 (P  0.05); for DHA, r  0.21 (P  0.05); for MQ, r  	0.11 (P  0.05); for LUM, r  0.14 (P  0.05), and for CQ, r  0.37 (P 
0.01). For pairs with P values greater than 0.05, there is no significant relationship between the two variables.
b Amplicon type is described in detail in Fig. 2, with the characterization of amplicon size and position of the amplified fragment carrying the pfmdr1 gene.
c Inhibitory concentrations previously published (36).
d P  0.001 (t test). Results previously published (36).
e P  0.005 (unpaired t test between amplicon type a and amplicon type other than a).
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